Memantine does not show intracellular block of the NMDA receptor channel

Chris G Parsons1, Kate E Gilling, Claudia Jatzke

  • 1Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, D-60318, Frankfurt, Germany. christopher.parsons@merz.de

Insights

Memantine does not block the N-methyl-D-aspartate (NMDA) receptor channel from the intracellular side, unlike magnesium ions (Mg2+). This finding suggests intracellular NMDA receptor blockade is not significant for memantine

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Magnesium ions (Mg2+) block the NMDA receptor channel from both extracellular and intracellular compartments.
  • Memantine achieves high intracellular concentrations, prompting investigation into its intracellular blocking potential.

Purpose of the Study:

  • To determine if memantine can block the NMDA receptor channel from the intracellular compartment.
  • To compare the intracellular blocking effects of memantine and Mg2+ on NMDA receptors.

Main Methods:

  • Expressed NR1a/NR2A receptors in Xenopus oocytes.
  • Utilized two-electrode voltage-clamp and patch-clamp recordings.
  • Applied Mg2+ and memantine to intracellular and extracellular sides of the receptor.

Main Results:

  • Mg2+ blocked the NMDA receptor channel from the intracellular side, with increased block at higher concentrations.
  • Memantine (30 microM) did not block the NMDA receptor channel from the intracellular compartment.
  • NMDA receptor rectification at positive potentials was observed with intracellular Mg2+ but not intracellular memantine.

Conclusions:

  • Intracellular block of the NMDA receptor by memantine is not a significant factor in its therapeutic effects.
  • The mechanism of memantine's therapeutic action likely does not involve intracellular NMDA receptor blockade.

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...